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Abstract The central nervous system mechanisms
involved in trigeminal autonomic cephalalgias, a group of
primary headaches characterized by strictly unilateral head
pain that occurs in association with ipsilateral craniofacial
autonomic features, are still not comprehensively under-
stood. However, functional imaging methods have revo-
lutionized our understanding of mechanisms involved in
these primary headache syndromes. The present review
provides a brief overview of the major modern functional
neuroimaging techniques used to examine brain structure,
biochemistry, metabolic state, and functional capacity. The
available functional neuroimaging data in cluster headache
and other TACs will thus be summarized. Although the
precise brain structures responsible for these primary
headache syndromes still remain to be determined, neuro-
imaging data suggest a major role for posterior hypothal-
amus activation in initiating and maintaining attacks.
Furthermore, pathophysiological involvement of the pain
neuromatrix and of the central descending opiatergic pain
control system was observed. Given the rapid advances in
functional and structural neuroimaging methodologies, it
can be expected that these non-invasive techniques will
continue to improve our understanding into the nature of
the brain dysfunction in cluster headache and other tri-
geminal autonomic cephalalgias.
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Introduction
Trigeminal autonomic cephalalgias (TACs), such as cluster
headache (CH), paroxysmal hemicrania (PH) and short-
lasting unilateral neuralgiform headache attacks with con-
junctival injection and tearing (SUNCT) are a group of
primary headaches which share the activation of the tri-
geminal nerve in mediating pain and of the parasympa-
thetic component of the seventh cranial nerve in producing
the local autonomic symptoms [1]. However, the CNS
mechanisms involved in these primary headaches are still
not comprehensively understood.
Modern methods of functional neuroimaging have revo-
lutionized our way of exploring brain function, and their
applicationinthestudyofTACshasprovidedgreatadvances
in the understanding of their pathophysiological facets.
Here, we will provide ﬁrst a brief overview of the
neuroimaging techniques used to study brain function in
TACs. Thereafter, we will review the knowledge acquired
with these functional neuroimaging methods on the path-
ophysiology of primary headaches.
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While early studies in trigeminal autonomic headache were
done exclusively with positron emission tomography
(PET), the development of new imaging techniques as well
as the increase in image resolution have led to an expansion
in the applications of magnetic resonance (MR) based
imaging methods in headache. Both PET and MR-based
imaging methods have now been widely used in trigeminal
autonomic headache research. As well as these imaging
methods that enable us to investigate the function of the
brain during headache attacks, structural and morphometric
methods, such as voxel-based morphometry, have also
become available. In contrast to conventional methods,
voxel-based morphometry allows the comparison of the
local concentration of gray matter between groups of
subjects and the correlation of whole-brain gray matter
density with clinical variables of the disease.
Single photon emission computed tomography
(SPECT)
First studies in headache research have applied SPECT, a
procedure based on nuclear medicine imaging techniques.
SPECT can be used to deﬁne a patient’s pathologic status
when neurologic or psychiatric symptoms cannot be
explained by structural neuroimaging ﬁndings [2]. Mole-
cules labeled with a radioactive isotope are administered by
IV injection. A positron-sensitive detector allows the
detection of photon emissions. SPECT isotopes are chosen
on the basis of their chemical, biologic, and nuclear
properties [3]. The main characteristics include: a half-life
long enough to allow tracer preparation, injection, and
uptake and image acquisition and short enough not to
deliver an unnecessary dose to the patient; gamma emis-
sion energy sufﬁciently high to escape from the patient, but
sufﬁciently low to facilitate collimation and detection and
favorable dosimetry to limit patient exposure [3]. The




123I-IMP), more recently replaced by technetium-Tc99m-
labeled hexamethylpropyleneamine oxime (Tc99m-
HMPAO) and Tc99m-ethyl cysteinate dimer (ECD). The
brain perfusion imaging agents 99mTc-HMPAO and
99mTc-ECD are sensitive indicators of regional cerebral
blood ﬂow (rCBF) changes and can detect a reduction in
blood ﬂow [2].
Positron emission tomography
In headache research many studies have applied PET. PET
is a nuclear medicine imaging technique that permits to
acquire images of physiologic function by studying cere-
bral blood ﬂow as an indirect marker of neuronal activity.
The scan uses a gamma-ray emitting radio-isotope bound
to a biologically active molecule. The radiotracers princi-
pally used are 2-deoxy-2-[18F] ﬂuoro-D-glucose (18FDG)
[4, 5],
15O labeled water (H2
15O) [6], or radioactively
labeled ligands that bind to speciﬁc receptors [7, 8]. After
seconds or few minutes following the injection or inhala-
tion of the radiopharmaceutical, the radio-isotope decays
emitting a positron, which moves a short distance before
annihilating with an electron. The annihilation produces a
couple of photons that are detected with a gamma camera.
In modern scanners, three-dimensional images of tracer
concentration within the body are then constructed by
computer analysis, accomplished with the aid of a CT
X-ray scan, performed at the same time. Radiopharma-
ceuticals most commonly used, such as 18FDG and H2
15O,
allow imaging of tissue metabolic activity, in terms of
regional glucose uptake or blood ﬂow changes, respec-
tively. Imaging of the tissue concentration of other types of
molecules of interest can be obtained by using different
tracers.
Magnetic resonance spectroscopy
Magnetic resonance spectroscopy (MRS) is based on the
principle that the resonance frequency of a nucleus depends
on its chemical environment, produces a small, but per-
ceptible, change in the resonance frequency of that nucleus.
This nuclear behavior is termed ‘‘chemical shift’’ and is
caused by the magnetic ﬁelds generated by circulating
electrons surrounding the nuclei, interacting with the main
magnetic ﬁeld. Protons (
1H) have been traditionally used
for MRS because of their high natural abundance in
organic structures and high nuclear magnetic sensitivity
compared with any other magnetic nuclei [9]. Moreover,
diagnostically resolvable hydrogen MR spectra may be
obtained with clinical instruments (1.5 T or greater) and
routine coils. MR spectroscopy allows mapping the distri-
bution of metabolite concentrations within small volumes
of cerebral tissue, termed volume of interest (VOI) [10].
Using long echo-times (TEs), the signal from most
metabolites in the brain is lost except for choline (Cho),
creatine (Cr), N-acetyl aspartate (NAA), and lactate. NAA
is accepted as a marker of neuronal density and viability.
Cho is a metabolic marker of membrane density and
integrity. The peak for Cr is a marker of energy metabo-
lism. Lactate appears under conditions where the aerobic
oxidation mechanism fails and anaerobic glycolysis takes
over. Lipids reﬂect necrotic processes [11]. Moreover,
other metabolites (e.g., myoinositol, glutamate, glutamine,
and glycine) can be identiﬁed by using short TEs [12].
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Functional MRI was used to generate the ﬁrst functional
magnetic resonance maps of human task activation. In
1990, Ogawa et al. [13] reported that MRI was sensitive
enough to show ‘‘blood oxygenation level-dependent’’
(BOLD) signal changes in vivo. Since it was known that
changes in neuronal activity were accompanied by local
changes in brain oxygen content [14], it became evident
that a technique based on the BOLD effect could poten-
tially be used to investigate neuronal activation through
changes induced in tissue oxygenation. The signal changes
in BOLD fMRI are determined by the paramagnetic
properties of deoxyhemoglobin (deoxy-Hb) [15]. Accord-
ing to the BOLD signal theory, these changes are deter-
mined by a marked increase in regional blood ﬂow.
Because blood oxygenation levels change rapidly follow-
ing the activity of neurons in a brain region, fMRI allows
researchers to localize brain activity on a second-by-second
basis, and within millimeters of its origin. In addition to the
BOLD effect, other mechanisms are supposed to contribute
to the endogenous MR contrast. It is well known that
inﬂow effects make some contribution to the functional
signal change [16].
Voxel-based morphometry
Voxel-based morphometry (VBM) permits to identify
volume differences in brain anatomy between groups of
subjects, performing statistical tests across all voxels in the
image [17]. The procedure involves the acquisition of T1-
weighted volumetric MRI scans that are registered onto the
same template image so that they are all in the same space,
to perform statistical analyses across multiple MRI scans
from different individuals. This process is known as spatial
normalization [18]. The spatially normalized images are
next segmented into gray matter (GM), white matter (WM)
and cerebrospinal ﬂuid (CSF). Although both gray and
white matter volumes can be assessed using VBM, the
majority of VBM studies concentrate on gray matter [18].
The images, after the normalization and segmentation, are
smoothed and processed to perform a parametric statistical
analysis [17]. All voxels that refute the null hypothesis and
show statistical signiﬁcance generate statistical maps that
are often shown as color maps with the scale representing
the t statistic [18]. However, in more recent studies, the
segmentation of images into GM, WM and CSF is ﬁrst
performed and then GM maps are applied a high-dimen-
sional DARTEL normalization modulating for nonlinear
effects [19, 20].
In the following section, we will summarize the results of
functional imaging studies on trigeminal autonomic head-
ache syndromes, showing how functional neuroimaging has
advanced our understanding of trigeminal autonomic head-
ache pathophysiology (Tables 1, 2).
Neuroimaging in trigeminal autonomic cephalalgias
The group includes cluster headache (CH), paroxysmal
hemicrania (PH), and short-lasting unilateral neuralgiform
headache attacks with conjunctival injection and tearing
(SUNCT). These syndromes differ in attack duration and
frequency and present different responses to therapy [21].
Cluster headache
CH is the most frequent syndrome. The pain is located
mainly around the orbital and temporal regions, though any
part of the head can be affected. The headache usually lasts
45–90 min but can range between 15 min and 3 h. Typi-
cally, this syndrome is characterized by a striking circan-
nual and circadian pattern. There is a clear male
preponderance.
Usually headache attacks cluster in time, lasting for
7 days to a year separated by remission periods lasting for
months or years (80–90% of patients). Sometimes attacks
recur for more than 1 year without remission periods, then
becoming chronic (10–20% of patients) [21, 22].
Early neuroimaging studies in cluster headache evalu-
ated cerebral blood ﬂow, using mainly SPECT. This semi-
quantitative method has not provided univocal results,
since some studies reported an increase, some a decrease
and others no differences in cortical blood ﬂow, possibly
because of methodological dissimilarities [23–27]. Di Piero
et al. [28], aiming to investigate brain response to pain in 7
cluster headache patients out of the bout compared to 12
healthy controls, recorded Xe-133 SPECT during experi-
mentally induced pain by means of a cold water pressor
test. They demonstrated less cerebral blood ﬂow modiﬁ-
cations in contralateral primary sensorimotor and thalamic
regions compared to healthy subjects only when the CPT
was performed on the CH side. This led the authors to
suggest the possible involvement of central tonic pain
mechanisms in the pathogenesis of cluster headache. Hsieh
and coworkers performed [
15O] butanol PET in 7 patients
affected by episodic CH (4 in and 3 out of the bout) during
nitroglycerine-induced pain. PET scan showed a signiﬁ-
cantly increased rCBF in the right caudal and rostrocaudal
anterior cingulate cortex (ACC), temporopolar region,
supplementary motor area, bilaterally in the primary motor
and premotor areas, opercular region, insula/putamen, and
lateral inferior frontal cortex. Moreover, a reduction in
rCBF bilaterally in the posterior–parietal cortex, occipito-
temporal region and prefrontal cortex was observed [29].
May and colleagues, scanning nine chronic CH patients
J Headache Pain (2012) 13:11–20 13
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Reference No. of subjects
and diagnosis





1 episodic CH During the attack SPECT No differences in mean CBF
Sakai et al.
[24]
9 episodic CH SPECT Increased CBF
Henry et al.
[25]
3 episodic CH Inside a bout during an
attack
SPECT No differences in mean CBF
Nelson et al.
[26]




SPECT Patients showed a variable pattern of
increased or decreased mean CBF
Krabbe et al.
[27]
18 episodic CH 18 outside the attacks
8 during the attack
SPECT No differences in mean CBF
Di Piero et al.
[28]
7 episodic CH Outside of a bout SPECT CBF lower in contralateral primary
sensorimotor and thalamic regions
compared to healthy subjects
Hsieh et al.
[29]
7 episodic CH 4 during the bout
3 out of the bout
(nitroglycerine-induced
attacks)
PET Increased rCBF in the right caudal and
rostrocaudal ACC, temporo-polar
region, supplementary motor area,
bilaterally in the primary motor area,
premotor areas, opercular region, insula/
putamen, and lateral inferior frontal
cortex
rCBF lower in the bilateral posterior




9 chronic CH During a bout
(nitroglycerine-induced
attacks)
PET Inferior hypothalamic grey matter
activation ipsilateral to the headache
side. Increased rCBF in the contralateral
ventroposterior thalamus, the anterior




1 chronic CH During a bout (spontaneous
attacks)
PET Inferior hypothalamic grey matter
activation. Increased rCBF in the medial




17 episodic CH 9 during a bout






Activation ACC bilaterally, ipsilateral
posterior thalamus, ipsilateral basal
ganglia, ipsilateral inferior posterior
hypothalamus, frontal lobes, insulae
bilaterally, contralateral inferior frontal
cortex.
Increased CBF in the internal carotid
artery ipsilateral to the headache side,






In- and outside of a bout FDG-PET Increased metabolism in the perigenual
ACC, posterior cingulate cortex, the
orbitofrontal cortex including the
nucleus accumbens, ventrolateral
prefrontal cortex, DLPFC and temporal
cortex, cerebellopontine area.
Hypometabolism in the perigenual





10 in- and 8 outside
of a bout
1H-MRS Reduction of NAA in the hypothalamus
of all the patient groups
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15O PET during nitroglycerine-induced attacks,
were the ﬁrst to clearly demonstrate inferior hypothalamic
gray matter activation ipsilateral to the headache side.
Moreover, they observed an increased rCBF in the con-
tralateral ventroposterior thalamus, the anterior cingulate
cortex, and in the insulae bilaterally as well [30]. Later,
other authors conﬁrmed these data in a spontaneous
headache attack of a chronic CH patient during an ongoing
H2
15O PET study [31]. The CH attack-induced activation
also increases in the medial thalamus and contralateral
perigenual ACC [31].
The exact role of the intracranial blood vessels in the
mechanism of cluster headache was investigated by May
et al. [31], who performed a H2
15O PET study in a group of
17 episodic CH patients (9 in the active period and 8 out of
their bout) and a MR angiography in a spontaneous CH and
capsaicin-induced pain in 4 healthy volunteers. H2
15O PET
study showed signiﬁcant activation during spontaneous or
nitroglycerine-induced headaches bilaterally in the ACC,
ipsilateral posterior thalamus, ipsilateral basal ganglia,
ipsilateral inferior posterior hypothalamus, both frontal
lobes, bilaterally in the insulae, and in the contralateral
inferior frontal cortex. In addition, they found activation in
large intracranial vessels on the PET scan which corre-
sponds to a signiﬁcantly increased blood ﬂow in the
internal carotid artery ipsilateral to the headache side, both
in CH patients and in experimentally induced pain [32].
The latter ﬁndings further support the neuronal nature of
the dysfunction in CH, conﬁrming that intracranial vascular
changes are not speciﬁc to headache but represent a generic
epiphenomenon of the pain.
Sprenger and colleagues [4] measured cerebral glucose
metabolism by means of FDG-PET in 11 episodic CH
patients during and outside the bout and compared these
Table 1 continued
Reference No. of subjects
and diagnosis
Timing of the scan Neuroimaging
techniques
Main results
Wang et al. [35] 47 episodic CH In- and outside of a bout
1H-MRS Reduction of NAA and Cho/Cr metabolite
ratio in the hypothalamus
May et al. [36] 25 episodic CH In- and outside of a bout VBM Increase in bilateral hypothalamic gray
matter volume
Sprenger et al. [6] 6 episodic CH
1 chronic CH
During the bout, but out of
an acute attack
PET with the opioidergic
ligand
[11C]diprenorphine
Decreased tracer binding in the pineal
gland
Morelli et al. [39] 4 episodic CH Inside the bout during an
acute attack
fMRI Activation of hypothalamus, pre-frontal
cortex, anterior cingulate cortex,
contralateral thalamus, ipsilateral basal











15O PET Activation in the contralateral posterior
hypothalamus, contralateral ventral
midbrain, ipsilateral lentiform nucleus,
anterior and posterior cingulate cortices,
bilateral insulae, bilateral frontal
cortices, contralateral temporal cortex,
contralateral postcentral gyrus,
precuneus, and contralateral cerebellum.
Indomethacin administration turned off
the persistent metabolic activation
observed during acute attack-off
indomethacin
May et al. [45] 1 SUNCT During 6 consecutive
attacks
fMRI Activation in the ipsilateral inferior
posterior hypothalamic gray matter
Cohen et al. [47] 2 SUNCT During the attacks fMRI Activation in the inferior posterior





During the attack fMRI Activation in the ipsilateral hypothalamic
gray matter, cingulate cortex, insula,
temporal cortex, and frontal cortex
Sprenger et al.
[48]
1 SUNCT During attacks induced
touching the upper with
the lower lip
fMRI Activation in the hypothalamic gray
matter bilaterally
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to those outside the bout, patients scanned during the bout
presented increased metabolism in the perigenual ACC,
posterior cingulate cortex, the orbitofrontal cortex includ-
ing the nucleus accumbens, ventrolateral prefrontal cortex,
dorsolateral prefrontal cortex (DLPFC) and temporal cor-
tex, and increased metabolism in cerebellopontine area.
Moreover, CH patients (in and out of the bout) compared to
healthy subjects revealed hypometabolism in the perige-
nual ACC, prefrontal and orbitofrontal cortex [4]. Inter-
estingly, the perigenual ACC was found to be activated in
chronic CH patients, unresponsive to pharmacological
therapy, who were treated successfully with occipital nerve
stimulation [33].
Further evidence for hypothalamic dysfunction in CH
arises from spectroscopic studies. A study with proton MR
spectroscopy (
1H-MRS) of 26 patients with CH (18 epi-
sodic, 10 in and 8 outside the bout, and 8 chronic) dem-
onstrated that the NAA, a marker of neuronal integrity, is
reduced in the hypothalamus of three subgroups when
compared to 12 healthy subjects [34]. These data have been
conﬁrmed with the same methodology in a group of 47
episodic CH patients by Wang and colleagues [35], who
found in addition, a reduction in the Cho/Cr metabolite
ratio, both during and out of the bout. This suggests that the
hypothalamus in cluster headache might be characterized
not only by a neuronal dysfunction but even by changes in
the membrane lipids.
With the voxel-based morphometric (VBM) analysis,
May and coworkers [36] studied 25 episodic patients with
CH and reported an increase in bilateral hypothalamic gray
matter volume, with similar results in patients examined
during and outside the bout [36]. Another larger VBM
study investigating 75 CH patients (22 episodic inside bout,
35 outside bout and 18 chronic CH) was unable to reveal
changes in hypothalamic area neither overall nor in sub-
groups [37].
VBM-MRI ﬁndings taken together with those provided
by
1HMRS may indicate that the hypothalamus of patients
with CH has an increased neuronal density with reduced
NAA, suggesting the presence of either immature or dys-
functional neurons [34, 38]. Moreover, these morphometric
and functional changes seem to be a permanent disease-
related dysfunction since they are not due to the CH history
or the cluster phase [34, 36].
Using PET with the opioidergic ligand [11C]diprenor-
phine in 7 CH patients (6 episodic and 1 chronic) who are
in bout but out of an acute attack, Sprenger and colleagues
demonstrated a decreased tracer binding in the pineal
gland, but not in any other brain structure commonly
claimed to be involved in cluster headache pathophysiol-
ogy [7, 36]. Furthermore, the authors found an inverse
relationship between the duration of cluster headaches and
opioid receptor binding in the ipsilateral hypothalamus and
bilateral cingulate cortices. The latter observation suggests
that descending opioidergic mechanisms in the pineal
gland and hypothalamus might be involved in the genera-
tion of cluster headache attacks.
The study of Morelli et al. [39] is the only one per-
forming fMRI in order to investigate the pattern of cerebral
activation during an attack of CH in four episodic patients,
showing activation of diencephalic regions, mainly the
hypothalamus. Additionally, they documented trends of
activation in cerebral areas involved in pain processing
Table 2 Synoptic table of neuroimaging studies showing three major observations relevant for the pathophysiology of cluster headache
Method Posterior hypothalamus activation Pain neuromatrix involvement Opiatergic system involvement
SPECT Di Piero et al. [28]
PET May et al. [30]
Sprenger et al. [31]
May et al. [32]
Matharu et al. [43]
Hsieh [29]
May et al. [25]
Sprenger et al. [31]
May et al. [32]
Sprenger et al. [4]
Matharu et al. [43]
Sprenger et al. [4]
Sprenger et al. [6]
MRI Lodi et al. [34]
Wang et al. [35]
Morelli et al. [39]
May et al. [45]
Cohen et al. [47]
Sprenger et al. [46–48]
Sprenger et al. [46–48]
Morelli et al. [39]
Sprenger et al. [46–48]
VBM May et al. [36]
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thalamus, ipsilateral basal ganglia and the insula and the
cerebellar hemispheres bilaterally) [39].
Paroxysmal hemicranias
PH is a relatively rare syndrome and the clinical features
are highly characteristic [40–42]. Patients typically have
unilateral, brief, severe attacks of pain, localized over the
ﬁrst division of the trigeminal nerve, associated with cra-
nial autonomic features that recur several times per day.
The duration of the pain is between 2 and 30 min with a
frequency of between 1 and 40 attacks per day. It is more
common in women and in chronic form. PH responds in a
dramatic and absolute fashion to indomethacin, hence the
importance of distinguishing it from CH and SUNCT,
which are not responsive to indomethacin. Activation of
the hypothalamic gray matter during attacks was also
observed in paroxysmal hemicranias. Matharu and
coworkers [43] were the ﬁrst to perform H2
15O PET in
seven patients affected by PH, scanned during acute attack-
off indomethacin or pain-free-off indomethacin and pain-
free due to indomethacin administration. The regions sig-
niﬁcantly activated during headache-off indomethacin
versus the pain-free phase were the contralateral posterior
hypothalamus, contralateral ventral midbrain, ipsilateral
lentiform nucleus, anterior and posterior cingulate cortices,
bilateral insulae, bilateral frontal cortices, contralateral
temporal cortex, contralateral postcentral gyrus, precuneus,
and contralateral cerebellum [43]. Interestingly, indo-
methacin administration turned off the persistent activation
observed during acute attack-off indomethacin. This study
supports the view of paroxysmal hemicrania as a central
nervous system disorder and demonstrates for the ﬁrst time
the metabolic correlation with indomethacin efﬁcacy.
Short-lasting unilateral neuralgiform headache attacks
with conjunctival injection and tearing
Among the other TACs, SUNCT is a very rare primary
headache syndrome, with a male prevalence, characterized
by strictly unilateral, severe, neuralgic attacks centered on
the ophthalmic trigeminal distribution in association with
both conjunctival injection and lacrimation [21, 44]. The
duration of each attack is between 5 and 240 s with a
frequency ranging between 3 and 200 per day. Although
there are marked differences in the clinical pictures of the
trigeminal autonomic syndromes, such as the frequency
and duration of attacks and the different approaches to
treatment, many of the basic features of SUNCT, such as
episodicity, autonomic symptoms, and unilaterality, are
shared by other headache types, such as cluster headache
and chronic paroxysmal hemicrania suggesting a
pathophysiological similarity to these syndromes. By
studying 6 consecutive spontaneous attacks of SUNCT
with fMRI in a 71-year-old woman, May et al. [45]
observed activation during the same scanning session in the
ipsilateral inferior posterior hypothalamic gray matter
during the attacks, compared with the pain-free state. The
same ipsilateral area activation was observed also in a
68-year-old man with an atypical case of TAC resembling
SUNCT [46]. Additionally, a clear trend of cingulate cor-
tex, insula, temporal and frontal cortices activation was
observed [46]. It has to be noted that activation of the
posterior hypothalamus was even bilaterally in the two
patients affected by SUNCT in the study by Cohen and
colleagues [47] and increases parametrically with increas-
ing levels of pain.
Bilateral posterior hypothalamus activation was also
observed in the fMRI study of Sprenger et al. [48] where a
49-year-old male patient was scanned during attacks of
SUNCT and pain-free state. Also in this case, multiple
activations were observed in brain regions involved in the
processing of pain [48].
Conclusions
The role of imaging in TACs has traditionally been
directed at ruling out treatable and reversible etiologies
(secondary forms of TAC). However, here we have
reviewed several studies which used neuroimaging to bet-
ter understand the pathophysiology of TACs.
Different brain imaging techniques were employed in
order to examine the structure, biochemistry, metabolic
state, and functional capacity of the TAC brains. All the
abnormalities shown by the imaging techniques can be
summarized in three major observations: (1) posterior
hypothalamic activation during the attacks; (2) involve-
ment of the pain matrix; and (3) of the central opioid
system (Fig. 1).
Hypothalamic hyperactivity ipsilateral to the headache
side in CH, contralateral in PH, and bilateral in SUNCT
were observed during the attacks in all the PET and fMRI
studies, with one exception [4]. This activation has not
been reported in between attacks of episodic CH. However,
hypothalamic activation is not a speciﬁc marker of tri-
geminal autonomic headaches, since it was observed even
during spontaneous migraine attacks without aura [49]. It is
noteworthy that the presence of hypothalamic activation in
other primary headaches or painful syndromes [50, 51]
does not necessarily refute speciﬁcity for this brain struc-
ture in initiating and maintaining an attack of trigeminal
autonomic cephalalgia, particularly cluster headache. In
fact, hypothalamic activation not only may reﬂect a general
antinociceptive response in healthy humans and in some
J Headache Pain (2012) 13:11–20 17
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tioning in cluster headache. As a matter of fact, in
patients treated with invasive neurostimulation procedures
(occipital nerve stimulation) due to the drug resistance of
their chronic cluster headache, the hypothalamic hyper-
activation still persists during the stimulator-on condition
and despite its clinical efﬁcacy [33]. It has been suggested
that persistent hypothalamic activation could be the factor
that contributes to generate a central permissive state
which predisposes to activation of the trigeminal system,
mediating pain, and of the parasympathetic reﬂex, pro-
ducing the autonomic symptoms [52]. The latter could
also help in explaining why patients still continue to
experience autonomic attacks during the neurostimula-
tion-on condition and why pain recurs when it is turned
off [33, 54].
For the sake of completeness, it has to be acknowledged
that there is still a controversy regarding the exact location
of this activation since several authors have questioned
whether it reﬂects a real hypothalamic activation or whe-
ther this corresponds to the activation of the ventral teg-
mental area or of other structures anatomically close to the
hypothalamus [55, 56]. The second major ﬁnding in tri-
geminal autonomic headache imaging studies was the
involvement of various areas belonging to the so-called
pain matrix, such as the prefrontal cortex, anterior cingu-
late cortex, thalamus, periaqueductal gray, basal ganglia,
the insula and the cerebellum. It is noteworthy that these
areas are also activated/deactivated in a broad range of
painful diseases from visceral to somatic, acute or chronic
[51]. For instance, changes in blood ﬂow in the thalamus,
insula and anterior cingulate cortex were observed during
episodic [57, 58] and chronic [5, 59] migraine attacks, and
also in chronic neuropathic [60] and visceral [61] pain. The
term pain neuromatrix is used to describe a set of brain
regions involved in human nociceptive processing. More-
over, the same brain areas are consistently involved in
descending antinociceptive processing. We can thus argue
that the metabolic changes in the pain neuromatrix could
be considered as the consequence of acute and, more so,
chronic pain states like that associated with episodic and
chronic cluster headache. This view is reinforced by the
fact that the hypermetabolic pattern of most of these brain
areas changes, almost restoring normal metabolism, after
CCH patients are successfully treated with neuromodula-
tory procedures [33, 53] or PH patients undergo efﬁcacious
treatment with indomethacin [43].
Several implications derive from the observation of
hypometabolism in the perigenual ACC (PACC) of epi-
sodic CH patients scanned outside, and much more during,
the bout compared to healthy subjects [4]. Since PACC
seems to play a major role in the central descending opi-
atergic pain control system, its deﬁciency may be a
mechanism that predisposes to the disorder and to its
recurrence [4]. The involvement of the opiatergic system in
CH pathophysiology is further conﬁrmed by the same
research group who found that opioid receptor availability
in the rostral ACC and hypothalamus reduces with the
duration of CH [7] and that low-dosage opioid (levo-
methadone) induces complete and long-lasting CH remis-
sion [62]. Moreover, in pharmacologically intractable CCH
patients who responded to occipital nerve stimulation, an
increased metabolism was observed in PACC in compari-
son to non-responders [33], further underlining the fact that
one of the pathophysiological mechanisms of treatment
efﬁcacy in CH is the restoration of normal opioid
analgesia.
In conclusion, to date, the most striking neuroimaging
ﬁndings in cluster headache are the posterior hypothalamic
activation during the attacks, with concomitant pain neu-
romatrix activation and opioid system involvement as
underlined by changes in perigenual ACC.
Given the rapid advances in functional and structural
neuroimaging methodologies, it can be expected that these
non-invasive techniques will continue to improve our
understanding into the nature of the brain dysfunction in
cluster headache and other trigeminal autonomic
cephalalgias.
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Fig. 1 Schematic brain representation summarizing the ﬁndings from
the previous studies in cluster headache with the possible pathophys-
iological consequences. ACC anterior cingulate cortex, pACC peri-
genual anterior cingulate cortex, PAG periaqueductal grey area, PFC
prefrontal cortex, S1 primary somatosensory area
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